The etiological agent for Chagas' disease is the protozoan parasite Trypanosoma cruzi, which affects 6 - 7 million people primarily in Latin America. The chronic stage of infection causes cardiomyopathy and the enlargement of other organs resulting in disease burden and death. There is an urgent need to replace the clinical therapeutics (benznidazole & nifurtimox) and this proposal focuses on a compound screen to observe a hit expansion with the target T. cruzi glucokinase.